Imbruvica is on track to be a top seller for J&J and Pharmacyclics for years to come

Imbruvica is on track to be a top seller for J&J and Pharmacyclics for years to come

Interesting insight into the revenues of the best selling cancer drugs in the USA. Many are familiar to us; Imbruvica of course and Revlimid (Lenalidomide), Rituxan (Rituximab/Mabthera) and perhaps Gleevec (Imatinib), the drug that did for CML what we are still looking for with CLL.

fool.com/investing/general/...

Even you don't read the article, just look at the comparison of the best selling US Cancer drugs in quarters after launch.

Note the forecast for Imbruvica net product revenue of approximately $1 billion in 2015, up 103% from 2014...

Neil

Last edited by

1 Reply

oldestnewest
  • Wow. That's some profit. Big research and development costs, no doubt, and losses elsewhere on experimental drugs that don't make it. But all the same, $1bn in a year is not to be sniffed at, huh?

You may also like...